EMA: Q&A Update; Expected studies for Quetiapine PR Tablets [BE/BA News]

posted by viveksraut – India, 2018-08-06 14:42  – Posting: # 19153
Views: 2,311

Dear all,

This is with reference to the point no. 14 (Quetiapine Lambda) of “Questions & Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP), EMA/618604/2008 Rev. 13” document published by EMA on 19 November 2015 )” to address specific questions in relation to pharmacokinetic evaluations and particularly the requirements and assessment of bioequivalence studies.

From the PKWP response to the point no. 14 question I understand the following;
So if applicant is developing generic version of Quetiapine prolonged release tablets and intended strengths are 25mg, 100mg, 200mg and 300 mg. Then in view of the PKWP response on this product and taking into account the guidance on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1), 20 Nov 2014, what are the studies expected by EMA for this product ? Your opinion please on this.

Regards : Vivek

Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,299 posts in 4,101 threads, 1,316 registered users;
online 14 (3 registered, 11 guests [including 7 identified bots]).

I have no opinion about ‘incurred samples’ –
an expression which has no easily understandable
meaning for me in the English language.    Nick Holford

BEBAC Ing. Helmut Schütz